The FDA has released preliminary findings from a study suggesting a link between the asthma drug Singulair (montelukast) and severe mental health issues, including suicidal ideation. The research indicates that montelukast can bind to brain receptors, raising concerns about its potential impact on mental health. More data is needed to confirm how the drug accumulates in the nervous system, the agency says.
Singulair and Mental Health Concerns
The FDA presented the preliminary results of its study on Singulair, also known generically as montelukast, at the American College of Toxicology meeting in Austin, Texas. The study's findings suggest that the drug's interaction with brain receptors may contribute to severe mental health side effects. While the FDA acknowledges the need for further research to understand the mechanisms involved, these initial findings warrant attention from healthcare professionals and patients alike.
Neurology Patient Groups Advocate for Increased Investment
In related news, neurology patient groups have voiced concerns over the pharmaceutical industry's level of investment in treatments for neurological disorders. A recent survey indicated that these patient groups are less satisfied with the current investment compared to their counterparts in other therapeutic areas. This call for increased spending highlights the significant unmet needs in treating diseases of the nervous system.
Pfizer's Q3 Sales Surge
In contrast to recent trends dominated by Eli Lilly and Novo Nordisk, Pfizer reported a notable 32% increase in sales during the third quarter. This growth positioned Pfizer as the top performer among large drugmakers, surpassing the sales growth figures of Novo Nordisk (21%) and Eli Lilly (20%).
Variability in Response to GLP-1 Weight Loss Drugs
Experts are reporting that a significant proportion of patients, potentially as high as 20%, may not respond effectively to GLP-1 drugs like Wegovy and Mounjaro for weight loss. While clinical trials have demonstrated an average weight loss of 15% to 22% among most participants, a subset of individuals experiences minimal benefit, underscoring the importance of managing patient expectations and exploring alternative treatment strategies.
